Searchable abstracts of presentations at key conferences in endocrinology

ea0069p5 | Poster Presentations | SFENCC2020

Isolated ACTH-deficiency following immune checkpoint inhibitors: diagnostic challenges demonstrated by a clinical case

Chatzimavridou-Grigoriadou Victoria , Higham Claire E , Lorigan Paul , Dhage Shaishav S , Trainer Peter J , Adam Safwaan

Case history: A 53-year-old male with melanoma who had a previous surgical excision of his skin lesion in December 2018 was being treated with adjuvant pembrolizumab. In June 2019 his treatment changed to combination immune checkpoint inhibitor therapy (ICPi) with ipilimumab and nivolumab due to radiological recurrence.Investigations: There were no pre-ICPi endocrine investigations available. In July 2019, thyroid function tests (TFTs) showed thyroid-sti...

ea0034p308 | Pituitary | SFEBES2014

Inhibition of lipolysis improves peripheral and hepatic insulin sensitivity and restores first phase insulin response in patients with acromegaly

McGlynn Stephen J , Bluck Les , Salgin Burak , Trainer Peter J , Williams Steve , Higham Claire E

Acromegaly causes impaired insulin sensitivity and reduced fat mass. Using acipimox to block lipolysis, the impact of free fatty acids (FFA) on insulin sensitivity in active acromegaly was investigated. 1H MRS was used to quantify triglyceride (TG) content of liver and muscle.Methods: 6 patients with active acromegaly (AA) (5M, age 59 (34–70), IGF-I (ng/ml) (median (range)) (452 (342–1002)) were studied on 2 visits; (i) baseline (BL)...

ea0032p965 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

Central hypothyroidism and adjusted thyroxine dose study (CHATS): impact of increasing free thyroxine levels in patients with hypopituitarism

Minder Anna-Elisabeth H , Jostel Andreas , Higham Claire E , Ryder W David J , Trainer Peter J , Shalet Stephen M

Introduction: Patients with pituitary deficiencies suffer from impaired quality of life regardless of substitution therapy with hydrocortisone, thyroxine (T4), sex hormones or GH. Central hypothyroidism (CH) is difficult to diagnose and treat because symptoms are non-specific and TSH-levels cannot be used for assessment. There is no consensus for the fT4-goal of thyroxine-replacement in patients with CH.Aim: To determine the impact ...

ea0021p280 | Pituitary | SFEBES2009

Treatment experience in 11 patients with gigantism

Higham Claire E , Emy Phillipe , Ferone Diego , Finke Reinhard , Laurberg Peter , Main Katharina , Maffei P , Martini C , Minuto Francesco , Rainegard Isabelle , Salzgeber Kirsten , Vogel C , Koltowska-Haggstrom Maria , Trainer Peter J

Gigantism is an extremely rare condition and hence the relevant literature is largely a series of case reports. We present data on patients with gigantism <20 years of age identified from Pfizer’s Acrostudy registry of patients treated with pegvisomant.Eleven patients (5M) were identified: IGF1 at diagnosis was 1.6×ULN (1.15–3.3), height +5 SDS (1.1–3.8) and age 14.5 years (4–19). The three youngest (4, 7 and 14 years) had pi...

ea0034oc6.5 | Clinical | SFEBES2014

Effectiveness of metyrapone in 195 patients with Cushing's syndrome

Daniel Eleni , Aylwin Simon , Mustafa Omar , Ball Steve , Munir Atif , Boelaert Kristien , Chortis Vasileios , Cuthbertson Daniel J , Daousi Christina , Rajeev Surya , Davis Julian , Cheer Kelly , Drake William , Gunganah Kirun , Grossman Ashley , Gurnell Mark , Powlson Andrew , Karavitaki Niki , Huquet Isabel , Kearney Tara , Mohit Kumar , Meeran Karim , Hill Neil , Rees Aled , Trainer Peter J , Lansdown Andrew J , Minder Anna-Elisabeth H , Newell-Price John

Background: Metyrapone is widely used in the UK for the control of cortisol excess in Cushing’s syndrome, but its use is not standardised. There are a few reports published on metyrapone use, mostly containing small patient numbers.Method: A retrospective survey was conducted across 13 tertiary centres. Using a standardised proforma, extensive data including monitoring and safety information were collected for patients with Cushing’s syndrome o...

ea0056oc12.5 | Novel aspects of puberty development and Cushing's disease | ECE2018

Diabetes mellitus and muscle weakness are independently associated with mortality in patients with Cushing’s syndrome. Data from ERCUSYN

Valassi Elena , Tabarin Antoine , Brue Thierry , Feelders Richard A , Reincke Martin , Neteia-Maier Romana , Toth Miklos , Yaneva Maria , Webb Susan M , Tsagarakis Stylianos , Chanson Philippe , Pfeifer Marija , Droste Michael , Komerdus Irina , Kastelan Darko , Maiter Dominique , Chabre Olivier , Franz Holger , Santos Alicia , Strasburger Christian J , Trainer Peter J , Newell-Price John , Ragnarsson Oskar

Background: Patients with active Cushing’s syndrome (CS) have increased mortality.Aims: Evaluate cause of death in a large cohort of CS patients, and establish factors associated with increased mortality.Methods: We analysed 1514 patients included in the European Registry on Cushing’s syndrome (ERCUSYN): 1022 (68%) had pituitary-dependent CS (PIT-CS), 379 (25%) adrenal-dependent CS (ADR-CS), 71 (5%) had an ectopic source ...